Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. - Wikidata - wikimedia - TriplyDB

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

http://www.wikidata.org/entity/Q35179985

about

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Present and future in the treatment of diabetic kidney disease Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples.Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment Cannabinoid receptor with an 'identity crisis' gets a second look Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?Endocannabinoid signaling at the periphery: 50 years after THC.β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner.The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.Activation of cannabinoid receptor 2 inhibits experimental cystitis Modulating the endocannabinoid system in human health and disease--successes and failures Role of the endocannabinoid system in diabetes and diabetic complications.Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice.Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with diet-induced obesity.Therapeutic approaches to diabetic nephropathy--beyond the RAS.Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.Acute kidney injury associated with smoking synthetic cannabinoid.Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.Marijuana Use and Estimated Glomerular Filtration Rate in Young Adults.Downstream effects of endocannabinoid on blood cells: implications for health and disease.Cannabinoids and the Kidney: Effects in Health and Disease.LOX-1-Targeted Iron Oxide Nanoparticles Detect Early Diabetic Nephropathy in db/db Mice.Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions.Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina.Synthetic marijuana and acute kidney injury: an unforeseen association Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury.Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an experimental diabetic rat model.Redox system and phospholipid metabolism in the kidney of hypertensive rats after FAAH inhibitor URB597 administration.Activation of cannabinoid receptor type 2 by JWH133 alleviates bleomycin-induced pulmonary fibrosis in mice.Selective cannabinoid 2 receptor stimulation reduces tubular epithelial cell damage following renal ischemia-reperfusion injury.Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.Cannabinoid receptor 1 disturbance of PPARγ2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli.Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression.Erzhi Formula Extracts Reverse Renal Injury in Diabetic Nephropathy Rats by Protecting the Renal Podocytes

P2860

Q24623282-75E68F64-2ACC-4B7A-97AF-B5549B58D4B3 Q26864133-CF85DBCA-1A8C-4BD3-8DEE-34EA10A22A7E Q27318021-3810A65B-001A-4C8E-8E5E-216F5E0EFBB3 Q27324350-79E0E844-A4D8-473A-845B-32B1F5E20557 Q29397935-30415D63-A9DB-45E7-A51C-5DC416DE78B2 Q33655394-5AAAFCBF-B373-41B5-AE65-C973111FCEA0 Q34186015-FF503394-EB12-4C8C-A80B-B8378F58A116 Q35572176-915B0D9C-03FF-4C2F-A204-1A353798053C Q35854652-BB319F6B-C165-458E-A4F2-77BFC685C48E Q35951992-47AA20FC-5221-4419-86B0-D71D33287E6E Q36346915-82C9DE4C-6937-4384-9AC6-FB3A88944FFB Q36506869-C1D9E25D-240A-4974-814D-632E16776991 Q36838206-7BE914A5-A029-460B-BBF7-A4DAF86643D9 Q36933683-2108E1E2-2629-4CCC-9CF2-131F98A89F6A Q37085532-A7261D9F-9077-47A6-95B3-A43BE731AD63 Q37330515-F831D8D2-425D-46A0-9E1F-C81A185C4115 Q37681996-6B988502-356A-4508-A3D0-91D9C6A69415 Q38209811-87A06348-78A2-4B1E-9B07-052A759519A5 Q38220272-03E03EC1-167C-43D7-AE80-511D57D5A086 Q38236657-F1D0EEBA-392E-40B9-AADA-8E2270AA7CDE Q38255902-22E0EB0E-D67A-4259-98AA-52CBA5EF24CA Q38398867-D93B398D-71C3-49E3-BC87-5AE15C51B50F Q38468985-1DD0406A-8E4C-4E7E-A845-88AAF8C2710B Q38651395-B8058BF1-B99F-4B63-AAA1-6A44FF60FE83 Q38911361-405DB0DA-94A7-4C71-A230-D9EFE6F4336B Q38924783-346BBA93-6C5D-45DD-9E98-22854436C278 Q39021787-8278C147-19E4-4D01-8D6F-F36302394A5F Q39321893-B2EDB04D-839D-4C68-85F4-EFE85D521B73 Q39719706-0FFBF4BF-C51D-4143-A440-330409A8D502 Q41150280-70479174-A27D-4A59-A3DB-69472B81401A Q45096687-A899B747-A44A-47B9-838F-203F73846D21 Q46249417-8F1E127C-5913-454A-B695-DBBF9F452A0E Q47138808-292E2A13-AAFD-46D7-AF7C-FFC364DDC0EC Q47349963-7FF8777F-32A6-4999-BFAD-EF2114C593F5 Q51067641-AC3D1E0B-D029-4E0A-8E6F-F3DAA1171654 Q52649284-9A57EF68-8AAB-4B01-8045-F6BC0403D081 Q55415494-6819518E-5C72-4226-9E91-9858CEFC5337 Q58711498-4A42D234-2A42-48A0-855C-B87CBC468E8A

P2860

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

http://www.wikidata.org/entity/Q35179985

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@ast

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@en

type

label

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@ast

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@en

prefLabel

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@ast

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@en

P1433

Q35179985-075FCDBD-31CE-4EE0-8C47-BAB95ACA22F2

P1476

Q35179985-57E0C2BC-A8C2-411B-881C-07ADA56480B3

P2093

Q35179985-5B36A4EC-212C-4B7C-BAAB-96A3D1FF7CED

Q35179985-6CAA904A-2242-4944-8B0B-ED72813F7F4A

Q35179985-6FFF6E61-4829-47B4-AAB1-EC3709C62A5B

Q35179985-88F9666E-A2BA-45B8-A5D5-2CED784E748E

Q35179985-8DD8A22F-FCC8-457A-87E0-C878E5BD2BE8

Q35179985-ACEAA022-5DC7-4A99-80D5-A0CBA64ABA3A

Q35179985-E8C50BC3-E44F-4341-9217-9F77F90A5AF5

P2860

Q35179985-02363EB7-EFAC-4C0C-BF17-A6F1A1907001

Q35179985-05532DE3-F0CB-4DB5-98FE-C4180D17C2BB

Q35179985-103EFDE6-2DE4-41C0-BCC8-54A44F177B93

Q35179985-16FE0A71-5015-446A-BBD3-D9C51664CDF2

Q35179985-1A2AB1FF-846B-411A-8FD5-EE852D6F59DB

Q35179985-1F6E6622-FDED-404B-8A5F-4EAE0653CBB8

Q35179985-31BF5C63-C699-464C-8AA5-7BAB51D20C7F

Q35179985-34D51AC2-96CD-4AD9-A5DA-61A3CAEA9133

Q35179985-42E4298B-4208-4AAF-BB57-0694099A50A5

Q35179985-4A081186-CE61-4079-B631-F1D0E36DDEBA

P304

Q35179985-DB43272C-B4DC-4D46-906D-B81A2B5B3223

P31

Q35179985-7CDC097E-DB32-4EE7-8802-EAF0E62447C8

P356

Q35179985-E1091E53-A4B6-4514-8152-5AF163D7D2B4

P407

Q35179985-4185360A-8EC5-45D0-8D98-5F43233C17B0

P433

Q35179985-7FAC5991-2E61-4589-AF68-F915771F5E27

P478

Q35179985-5EBCB693-5598-4C10-8109-2C5A2EC7D84B

P50

Q35179985-2DCE9790-8C74-4B3A-BC35-A83934D819F9

Q35179985-BA8E51DC-37B2-4B72-A669-16A78DBE5231

Q35179985-EA0EC26A-5D93-40F2-BFFA-82F294ED4FA4

P577

Q35179985-DCF290D0-E167-486D-9F2F-E91407998B09

P5875

Q35179985-16C31446-EFEA-4D29-81FD-5638D494B6D1

P698

Q35179985-B5E2C64F-45E9-43C4-BC9F-FF29048EBEA4

P921

Q35179985-2BB050C0-CFE6-4FBD-9AE9-0F7213038ACA

Q35179985-C26D7FE3-84AF-40E3-BC7B-035ABF3AAEB1

Q35179985-fd3bb914-69db-452b-9acc-8accb68ba0e4

P932

Q35179985-CECBA5EB-07CF-4C5F-AA04-D7FEBAAC95A7

P356

P1433

P1476

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.

@en

P2093

Federica Barutta

http://www.w3.org/2001/XMLSchema#string

Gabriella Gruden

http://www.w3.org/2001/XMLSchema#string

Gennaro Salvidio

http://www.w3.org/2001/XMLSchema#string

Maria Pia Rastaldi

http://www.w3.org/2001/XMLSchema#string

Paolo Cavallo Perin

http://www.w3.org/2001/XMLSchema#string

Roberto Gambino

http://www.w3.org/2001/XMLSchema#string

Silvia Pinach

http://www.w3.org/2001/XMLSchema#string

P2860

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis

Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.

Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients.

Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy.

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.

CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

P304

2386-2396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB10-1809

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Vincenzo Di Marzo

Fabiana Piscitelli

Graziella Bruno

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51541592

http://www.w3.org/2001/XMLSchema#string

P698

21810593

http://www.w3.org/2001/XMLSchema#string

P921

cannabinoid receptor

P932

3161308

http://www.w3.org/2001/XMLSchema#string